1. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. (August 2018) Authors: Berdeja, J.; Palandri, F.; Baer, M.R.; Quick, D.; Kiladjian, J.J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P.L.; Gerds, A.T. Journal: Leukemia research Issue: Volume 71(2018) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗